AR020892A2 - Un procedimiento para ensayar la influencia de secuencias de acido nucleico no codificadores de la region de un gen diana presente endogenamente en una celula eucariotica sobre la expresion de dicho gen diana. - Google Patents

Un procedimiento para ensayar la influencia de secuencias de acido nucleico no codificadores de la region de un gen diana presente endogenamente en una celula eucariotica sobre la expresion de dicho gen diana.

Info

Publication number
AR020892A2
AR020892A2 ARP990105096A ARP990105096A AR020892A2 AR 020892 A2 AR020892 A2 AR 020892A2 AR P990105096 A ARP990105096 A AR P990105096A AR P990105096 A ARP990105096 A AR P990105096A AR 020892 A2 AR020892 A2 AR 020892A2
Authority
AR
Argentina
Prior art keywords
diana
gene
expression
nucleic acid
cell
Prior art date
Application number
ARP990105096A
Other languages
English (en)
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR020892(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of AR020892A2 publication Critical patent/AR020892A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Abstract

Un procedimiento para ensayar la influencia de secuencias de ácido nucleico no codificadoras de la region de un gen diana presente endogenamente en unacélula eucariotica sobre la expresion de dicho gen diana, procedimiento que comprende las etapassi guientes: (a) la célula es transfectada con un vector quecomprende (i) una secuencia de control de expresion heterologa activa o activable en la célula, enlazada operativamente con un gen reporter, y (ii) fragmentosde ácido nucleico de la regiondel gen diana no codificadores del lado 5 y/o del lado 3, (b) la célula es cultivada bajo condiciones en las cuales lasecuencia de control de expresion es activa, y (c) se mide la expresion del gen reporter.
ARP990105096A 1997-12-01 1999-10-08 Un procedimiento para ensayar la influencia de secuencias de acido nucleico no codificadores de la region de un gen diana presente endogenamente en una celula eucariotica sobre la expresion de dicho gen diana. AR020892A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97121075 1997-12-01

Publications (1)

Publication Number Publication Date
AR020892A2 true AR020892A2 (es) 2002-06-05

Family

ID=8227717

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP980106075A AR018022A1 (es) 1997-12-01 1998-12-01 UN PROCEDIMIENTO PARA LA MODIFICACIoN DE LA EXPRESIoN DE UNA SECUENCIA DE ÁCIDO NUCLEICO PRESENTE ENDoGENAMENTE EN UNA CÉLULA EUCARIoTICA, UN VECTOR PARA LA RECOMBINACIoN HOMoLOGA Y UNA CÉLULA EUCARIoTICA, PREFERENTEMENTE UNA CÉLULA HUMANA QUE NO PUEDE DAR LUGAR A UN ORGANISMO ENTERO.
ARP990105095A AR020750A2 (es) 1997-12-01 1999-10-08 Un procedimiento para la modificacion de la expresion de una secuencia de acido nucleico presente endogenamente en una celula humana y una celula humana obtenida por dicho procedimiento que no puede dar lugar a un individuo completo.
ARP990105096A AR020892A2 (es) 1997-12-01 1999-10-08 Un procedimiento para ensayar la influencia de secuencias de acido nucleico no codificadores de la region de un gen diana presente endogenamente en una celula eucariotica sobre la expresion de dicho gen diana.
ARP990105097A AR020893A2 (es) 1997-12-01 1999-10-08 UN PROCEDIMIENTO PARA PROVEER UNA CÉLULA EUCARIoTICA DHFR NEGATIVA, UN PROCEDIMIENTO PARA INTRODUCIR DE UN GEN DHFR HETERoLOGO EN UNA CÉLULA EUCARIoTICA, UN VECTOR PARA RECOMBINACIoN HOMoLOGA Y UNA CÉLULA EUCARIoTICA, PREFERENTEMENTE UNA CÉLULA HUMANA QUE NO PUEDE DAR LUGAR A UN ORGANISMO ENTERO.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP980106075A AR018022A1 (es) 1997-12-01 1998-12-01 UN PROCEDIMIENTO PARA LA MODIFICACIoN DE LA EXPRESIoN DE UNA SECUENCIA DE ÁCIDO NUCLEICO PRESENTE ENDoGENAMENTE EN UNA CÉLULA EUCARIoTICA, UN VECTOR PARA LA RECOMBINACIoN HOMoLOGA Y UNA CÉLULA EUCARIoTICA, PREFERENTEMENTE UNA CÉLULA HUMANA QUE NO PUEDE DAR LUGAR A UN ORGANISMO ENTERO.
ARP990105095A AR020750A2 (es) 1997-12-01 1999-10-08 Un procedimiento para la modificacion de la expresion de una secuencia de acido nucleico presente endogenamente en una celula humana y una celula humana obtenida por dicho procedimiento que no puede dar lugar a un individuo completo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP990105097A AR020893A2 (es) 1997-12-01 1999-10-08 UN PROCEDIMIENTO PARA PROVEER UNA CÉLULA EUCARIoTICA DHFR NEGATIVA, UN PROCEDIMIENTO PARA INTRODUCIR DE UN GEN DHFR HETERoLOGO EN UNA CÉLULA EUCARIoTICA, UN VECTOR PARA RECOMBINACIoN HOMoLOGA Y UNA CÉLULA EUCARIoTICA, PREFERENTEMENTE UNA CÉLULA HUMANA QUE NO PUEDE DAR LUGAR A UN ORGANISMO ENTERO.

Country Status (16)

Country Link
US (1) US7008764B1 (es)
EP (3) EP0957165B1 (es)
JP (1) JP4629813B2 (es)
KR (1) KR100367062B1 (es)
CN (2) CN1232644C (es)
AR (4) AR018022A1 (es)
AT (3) ATE318904T1 (es)
AU (1) AU757930B2 (es)
BR (1) BR9805682A (es)
CA (1) CA2252970C (es)
DE (3) DE59813976D1 (es)
DK (3) DK0919619T4 (es)
ES (3) ES2259422T3 (es)
PT (3) PT957165E (es)
TR (1) TR199802503A3 (es)
ZA (1) ZA9810915B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278021A3 (en) * 1999-11-01 2011-05-18 Novartis Vaccines and Diagnostics, Inc. Expression vectors, transfection systems, and method of use thereof
CA2401677A1 (en) * 2000-03-03 2001-09-13 University Of Utah Research Foundation Gene targeting method
DE10023887A1 (de) * 2000-05-17 2001-11-29 Axel Haverich Verfahren zur transienten Insertion genetischer Elemente
ATE375388T1 (de) 2001-07-27 2007-10-15 Us Gov Health & Human Serv Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden
CA2474486C (en) 2002-01-23 2013-05-14 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
CA2579677A1 (en) * 2004-09-16 2006-03-30 Sangamo Biosciences, Inc. Compositions and methods for protein production
KR101419729B1 (ko) * 2005-07-26 2014-07-17 상가모 바이오사이언스 인코포레이티드 외래 핵산 서열의 표적화된 통합 및 발현
CN103484496A (zh) * 2013-07-31 2014-01-01 新乡医学院 一种报告基因重组在染色体目的基因上的方法、位点及用途
US9857328B2 (en) 2014-12-18 2018-01-02 Agilome, Inc. Chemically-sensitive field effect transistors, systems and methods for manufacturing and using the same
US10020300B2 (en) 2014-12-18 2018-07-10 Agilome, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
US10006910B2 (en) 2014-12-18 2018-06-26 Agilome, Inc. Chemically-sensitive field effect transistors, systems, and methods for manufacturing and using the same
US9859394B2 (en) 2014-12-18 2018-01-02 Agilome, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
WO2016100049A1 (en) 2014-12-18 2016-06-23 Edico Genome Corporation Chemically-sensitive field effect transistor
US9618474B2 (en) 2014-12-18 2017-04-11 Edico Genome, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
EP3459115A4 (en) 2016-05-16 2020-04-08 Agilome, Inc. GRAPHEN-FET DEVICES, SYSTEMS AND METHODS FOR USE THEREOF FOR SEQUENCING NUCLEIC ACIDS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568772A (en) * 1896-10-06 Albert s
CA1293460C (en) 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
GB2187415A (en) 1986-03-05 1987-09-09 Deere & Co Machine for forming cylindrical bales of crop
JPS62265992A (ja) * 1986-05-12 1987-11-18 Ajinomoto Co Inc ヒト細胞を用いる有用物質の製造方法
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
EP0747485B1 (en) * 1989-11-06 1998-12-02 Cell Genesys, Inc. Production of proteins using homologous recombination
JP3501286B2 (ja) * 1989-12-22 2004-03-02 アプライド リサーチ システムズ，エーアールエス ホールディング ナームロゼ ベノートスハップ 一定の細胞系又は微生物の内因性遺伝子の発現特徴の変性のための方法
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1992015694A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
WO1993015191A1 (en) * 1992-01-24 1993-08-05 Life Technologies, Inc. Modulation of enzyme activities in the in vivo cloning of dna
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5527695A (en) 1993-01-29 1996-06-18 Purdue Research Foundation Controlled modification of eukaryotic genomes
JP3654446B2 (ja) * 1993-12-23 2005-06-02 メルク アンド カンパニー， インコーポレイテッド マウス細胞のための相同的組換え抗体発現系
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US5695977A (en) * 1995-08-31 1997-12-09 Genetic Information Research Institute Site directed recombination
AUPN903196A0 (en) * 1996-03-29 1996-04-26 Australian National University, The Single-step excision means
US6020144A (en) * 1996-09-12 2000-02-01 Symbiontics, Inc. Sustained delivery device comprising a Leishmania protozoa and methods of making and using the same

Also Published As

Publication number Publication date
DE59813413D1 (de) 2006-04-27
EP0919619A2 (de) 1999-06-02
EP0957165B1 (de) 2007-04-18
AU9328498A (en) 1999-06-17
EP0919619A3 (de) 1999-07-21
PT1464705E (pt) 2006-08-31
ES2258809T5 (es) 2013-09-05
KR100367062B1 (ko) 2004-05-31
CN1590551A (zh) 2005-03-09
EP1464705A1 (de) 2004-10-06
EP1464705B1 (de) 2006-03-15
AR020893A2 (es) 2002-06-05
PT957165E (pt) 2007-07-19
ES2259422T3 (es) 2006-10-01
ES2258809T3 (es) 2006-09-01
CN1240829A (zh) 2000-01-12
ZA9810915B (en) 2000-05-30
TR199802503A2 (xx) 1999-06-21
BR9805682A (pt) 2000-04-11
JPH11225785A (ja) 1999-08-24
DK1464705T3 (da) 2006-07-24
CN100519751C (zh) 2009-07-29
CA2252970C (en) 2011-11-15
DK0919619T4 (da) 2013-09-23
EP0957165A3 (de) 2000-10-04
PT919619E (pt) 2006-07-31
AR020750A2 (es) 2002-05-29
US7008764B1 (en) 2006-03-07
DK0957165T3 (da) 2007-07-30
ATE360067T1 (de) 2007-05-15
DE59813976D1 (de) 2007-05-31
CN1232644C (zh) 2005-12-21
DE59813438D1 (de) 2006-05-11
ES2284228T3 (es) 2007-11-01
DK0919619T3 (da) 2006-07-10
KR19990062655A (ko) 1999-07-26
JP4629813B2 (ja) 2011-02-09
CA2252970A1 (en) 1999-06-01
AR018022A1 (es) 2001-10-31
EP0919619B2 (de) 2013-06-19
EP0957165A2 (de) 1999-11-17
ATE320491T1 (de) 2006-04-15
AU757930B2 (en) 2003-03-13
ATE318904T1 (de) 2006-03-15
EP0919619B1 (de) 2006-03-01
TR199802503A3 (tr) 1999-06-21

Similar Documents

Publication Publication Date Title
AR020892A2 (es) Un procedimiento para ensayar la influencia de secuencias de acido nucleico no codificadores de la region de un gen diana presente endogenamente en una celula eucariotica sobre la expresion de dicho gen diana.
Ryazanov Ca2+/calmodulin-dependent phosphorylation of elongation factor 2
Ramachandran et al. Chemical characterization of distinct subunits of pig heart DPN-specific isocitrate dehydrogenase.
DE69027526T2 (de) Herstellung von proteinen mittels homologer rekombination
BR9808584A (pt) Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
ES2013324A6 (es) Un metodo mejorado para producir una proteina heterologa.
ES2109924T3 (es) Metodo rapido, versatil y simple de expresion de genes en celulas eucarioticas.
NO972935D0 (no) Forbedringer i eller vedrörende endometriefunksjon
BR9813608A (pt) Polipeptìdeo isolado, sequências de ácido nucleico isolado e mutante, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, processos para produzir uma sequência de ácido nucleico mutante, para produzir um polipeptìdeo, para produzir um mutante de uma célula originária e para produzir uma proteìna, e, célula mutante
AU5222498A (en) Type i recombinant clostridium histolyticum collagenase and its use for isolating cells and cell aggregates
ES2059361T3 (es) Complejo de proteinas recombinantes que tiene actividad de factor viii:c su produccion y uso.
ATE326537T1 (de) Schnell erzeugung von stabilen säugertier- zellinien mit gewinnung eines hohen gehalts von recombinanten proteine
TR200000288T2 (tr) İnsülin C-peptidin rekombinan ekspresyonu.
Lee et al. Histone methylation during hepatic regeneration in rat
ATE546531T1 (de) Transaktivierungssystem für säugerzellen
ES2043610T3 (es) Procedimiento para la produccion de un polipeptido hibrido del tipo activador de plasminogeno.
FI945877A0 (fi) Menetelmä proteiini C:n tuottamiseksi
DE69801573D1 (de) Positives elektrodenmaterial auf basis von titanoxysulfid für elektrochemischen generator und verfahren zu dessen herstellung
Steinert et al. The synthesis of hair keratin proteins in vitro
Mizobe et al. Induction of a specific protein by oestradiol in rat pineals in culture
Righetti et al. Charge heterogeneity of recombinant pro-urokinase and urinary urokinase, as revealed by isoelectric focusing in immobilized pH gradients
DE69535024D1 (de) Verpackungszellinie zur transkomplementierung von defektiven retroviren-vektoren
Fiscus et al. Quantification of apoptotic DNA fragmentation in a transformed uterine epithelial cell line, HRE-H9, using capillary electrophoresis with laser-induced fluorescence detector (CE-LIF)
ATE51025T1 (de) Krebsspezifische dna.
NZ332555A (en) Gene expression in monocytes and macrophages associated with the CD68 gene

Legal Events

Date Code Title Description
FG Grant, registration